Results 51 to 60 of about 152,297 (198)

Brain natriuretic peptide and NT-proBNP levels reflect pulmonary artery systolic pressure in trekkers at high altitude. [PDF]

, 2013
Our objective was to evaluate the utility of the natriuretic peptides BNP (brain natriuretic peptide) and NT-proBNP as markers of pulmonary artery systolic pressure (PASP) in trekkers ascending to high altitude (HA). 20 participants had BNP and NT-proBNP
Begley, J, Boos, C, Foxen, S, Hawkins, A, Mellor, A, O'Hara, J, Smith, C, Stacey, M, Woods, DR, Yarker, J   +9 more
core  

Regulated Inositol‐Requiring Protein 1‐Dependent Decay as a Mechanism of Corin RNA and Protein Deficiency in Advanced Human Systolic Heart Failure [PDF]

, 2014
BACKGROUND: The compensatory actions of the endogenous natriuretic peptide system require adequate processing of natriuretic peptide pro‐hormones into biologically active, carboxyl‐terminal fragments.
Barton, P, Dries, DL, Felkin, LE, Lee, R, Rame, JE, Xu, B   +5 more
core   +1 more source

TRIM40 Drives Pathological Cardiac Hypertrophy and Heart Failure via Ubiquitination of PKN2

Advanced Science, EarlyView.
This study identifies the E3 ligase TRIM40 as a key driver of pathological cardiac hypertrophy. TRIM40 binds PKN2 via its B‐box domain and, through its C29‐dependent catalytic activity, mediates K63‐linked ubiquitination of PKN2. This modification enhances PKN2 phosphorylation at Ser815, thereby driving hypertrophy.
Risheng Zhao, Xiaoli Cui, Huizhu Du, Zhuoqun Wang, Chang Liu, Linxin Zhang, Jianing Qi, Di Yang, Hui Yu, Shuang Yan, Wei Liu, Haiming Sun, Mengyang Wang   +12 more
wiley   +1 more source

The influence of proteasome inhibitor on the expression of cardiomyocytes damage markers after incubation with doxorubicin

Current Issues in Pharmacy and Medical Sciences, 2014
The aim of the study was to verify the thesis that the cardiotoxic effects of doxorubicin are connected with activation of the ubiquitin - proteasome pathway followed by protein degradation.
Tereszkiewicz Sylwia, Matysiak Wlodzimierz, Mandziuk Slawomir, Korga Agnieszka, Oleksiejuk Malgorzata, Hejna Marcin, Korobowicz-Markiewicz Agnieszka, Iwan Magdalena, Dudka Jaroslaw   +8 more
doaj   +1 more source

B-Type Natriuretic Peptide (BNP) Revisited—Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?

Biology, 2022
Myocardial wall stress, cytokines, hormones, and ischemia all stimulate B-type (or brain) natriuretic peptide (BNP) gene expression. Within the myocardium, ProBNP-108, a BNP precursor, undergoes glycosylation, after which a portion is cleaved by furin ...
Toshio Nishikimi, Yasuaki Nakagawa
doaj   +1 more source

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in AML Induction Therapy

American Journal of Hematology, EarlyView.
Early cardiac biomarker monitoring in AML induction therapy showed significantly higher hsTnT levels after daunorubicin 90 mg/m2 compared with 60 mg/m2, indicating a dose‐dependent early myocardial effect. ABSTRACT Anthracyclines are an essential component of induction therapy for acute myeloid leukemia (AML), but their optimal dosing and the ...
Stefan Markus Dendorfer, Katharina Schmidt‐Brücken, Michael Kramer, Björn Steffen, Christoph Schliemann, Jan‐Henrik Mikesch, Nael Alakel, Regina Herbst, Mathias Hänel, Maher Hanoun, Martin Kaufmann, Barbora Weinbergerova, Kerstin Schäfer‐Eckart, Tim Sauer, Andreas Neubauer, Andreas Burchert, Claudia D. Baldus, Jolana Mertová, Edgar Jost, Dirk Niemann, Jan Novák, Stefan W. Krause, Sebastian Scholl, Andreas Hochhaus, Gerhard Held, Tomáš Szotkowski, Andreas Rank, Christoph Schmid, Lars Fransecky, Sabine Kayser, Markus Schaich, Frank Fiebig, Annett Haake, Johannes Schetelig, Jan Moritz Middeke, Friedrich Stölzel, Uwe Platzbecker, Christian Thiede, Carsten Müller‐Tidow, Wolfgang E. Berdel, Gerhard Ehninger, Jiri Mayer, Hubert Serve, Martin Bornhäuser, Christoph Röllig   +44 more
wiley   +1 more source

The potential of cardiac markers to improve patient management [PDF]

Journal of Medical Biochemistry, 2008
B-type natriuretic peptide (BNP) is a quantitative marker for heart failure. The use of BNP in patients with dyspnea has consistently shown to improve patient management and reduce treatment cost.
Müller Christian
doaj  

Impact of Rapid Exome Sequencing on Pediatric Patients With Cardiomyopathy and Acute Heart Failure

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Few studies describe the impact of rapid exome sequencing (ES) on pediatric cardiomyopathy in urgent clinical settings. Here, we retrospectively report the impact of rapid singleton ES in pediatric patients presented with acute heart failure and isolated cardiomyopathy or myocarditis, between 2021 and 2023 at a single tertiary care center.
Tameemi Abdalla Moady, Tova Hershkovitz, Clair Habib, Ori Attias, Amir Hadash, Galit Tal, Asaad Khoury, Josef Ben‐Ari, Danny Eytan, Tamar Paperna, Karin Weiss   +10 more
wiley   +1 more source

Biomarkers Beyond the Natriuretic Peptides for Chronic Heart Failure: Galectin-3 and Soluble ST2. [PDF]

, 2012
B-type natriuretic peptide (BNP) and NT-proBNP are widely used plasma biomarkers for the diagnosis of acute decompensated heart failure and prognosis for future cardiac disease.
Wu, Alan HB
core   +4 more sources

Pitavastatin ameliorates myocardial damage by preventing inflammation and collagen deposition via reduced free radical generation in isoproterenol-induced cardiomyopathy

Clinical and Experimental Hypertension, 2019
Pitavastatin inhibits 3 hydroxy 3 methyl glutaryl coenzyme A (HMGCoA) reductase enzyme, preventing cholesterol synthesis along with elevating high density apolipoprotein A1 (Apo-A1).
Ramsha Iqbal, Md Sayeed Akhtar, Md Quamrul Hassan, Zeeba Jairajpuri, Mohd. Akhtar, Abul Kalam Najmi   +5 more
doaj   +1 more source